Founded in 2013, Mimetas develops Organ-on-a-Chip technology for testing new medicines. Its unique microfluidic technology enables the testing of new medicines in high-throughput on miniaturised organ models. These models have better predictability compared to laboratory animals and conventional cell culture models. The basis under Mimetas comprises a unique prototyping and production platform, a world-leading position in passive microfluidics and a unique value proposition based on Organ-on-a-Chip technology. Mimetas works for most major pharmaceutical companies, developing tailored Organ-on-a-Chip models and assays for toxicology, disease modelling, and transport assays.
Dr. Paul Vulto
Dr. Paul Vulto is co-founder and Managing director of Mimetas.
He is a scientist-entrepreneur with over 15 years of international experience in microfluidics and Lab-on-a-Chip technology. His expertise will be a valuable asset in the development of the industrial quality microfluidic platform.
As work package leader for WP2 his main task will be to facilitate all collaborators in developing a validated high throughput in vitro screening platform for PD (PD-OrganoPlate™). Through Mimetas as an SME, he is capable of further developing the PD-OrganoPlate™ as a product for the pharmaceutical market. Mimetas will contribute to WP4 (samples) and WP7 (entrepreneurial activities).
Dr. Karlijn Wilschut
Dr. Karlijn Wilschut is Senior Scientist Application Development at Mimetas.
She specialises in stem cell biology over the past 15 years and leading several neuronal projects at Mimetas.
Her work in the project will contribute to the development of a high-throughput in vitro screening platform for Parkinson disease using the Mimetas OrganoPlate(R) and is leading this WP2.
Bjorn de Wagenaar
Chiwan Chiang, MSc, is a Junior Scientist Application and Development at Mimetas.
She specialises in the 3D cell culture of CNS cells in the OrganoPlate®. Her work in the SysMedPD project will contribute in the generation of a robust and efficient differentiation protocol of iPSC into midbrain-like dopaminergic neurons in the OrganoPlate®. Hence, to develop an industrial quality, microfluidic, iPSC-derived PD model for high-throughput screening.